Exact Sciences Corp. (EXAS) Social Stream

Exact Sciences Corp. (EXAS): $42.14

0.00 (0.00%)

POWR Rating

Component Grades








Featured Post From StockTwits About EXAS


Exact will be the first company that successfully develops and commercializes liquid biopsy screening. My bet. I do like other companies working toward this including GH and ILMN. Own ILMN too in decent size for 5 years. EXAS for 7 years.

This is not easy, but will be disruptive science. We will and should move away from expensive and invasive screening tests as time moves forward. It is a matter of when.

Conroy is a patent attorney who understands process deeply. For those new here, were you aware that Cologuard was approved by the FDA and CMS at the same time? Pretty impressive.
bluejay53, published August 14, 2021

Loading social stream, please wait...

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!